A detailed history of Huntington National Bank transactions in Alkermes Plc. stock. As of the latest transaction made, Huntington National Bank holds 305 shares of ALKS stock, worth $8,448. This represents 0.0% of its overall portfolio holdings.

Number of Shares
305
Previous 332 8.13%
Holding current value
$8,448
Previous $8,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$23.01 - $28.55 $621 - $770
-27 Reduced 8.13%
305 $8,000
Q2 2024

Aug 08, 2024

SELL
$23.21 - $27.24 $719 - $844
-31 Reduced 8.54%
332 $8,000
Q1 2024

May 03, 2024

SELL
$26.4 - $32.56 $52,140 - $64,306
-1,975 Reduced 84.47%
363 $9,000
Q4 2023

Feb 07, 2024

BUY
$23.37 - $28.68 $44,613 - $54,750
1,909 Added 444.99%
2,338 $64,000
Q3 2023

Nov 08, 2023

BUY
$27.17 - $31.97 $10,134 - $11,924
373 Added 666.07%
429 $12,000
Q2 2023

Aug 11, 2023

BUY
$28.34 - $33.63 $56 - $67
2 Added 3.7%
56 $1,000
Q1 2023

May 10, 2023

SELL
$25.31 - $29.02 $101 - $116
-4 Reduced 6.9%
54 $1,000
Q4 2022

Feb 09, 2023

BUY
$21.94 - $26.24 $65 - $78
3 Added 5.45%
58 $1,000
Q3 2022

Nov 07, 2022

BUY
$22.0 - $31.87 $44 - $63
2 Added 3.77%
55 $1,000
Q2 2022

Aug 09, 2022

BUY
$26.4 - $30.54 $1,372 - $1,588
52 Added 5200.0%
53 $2,000
Q2 2019

Jul 23, 2019

BUY
$21.47 - $37.33 $21 - $37
1 New
1 $0
Q1 2019

Apr 09, 2019

SELL
$28.4 - $36.49 $28 - $36
-1 Closed
0 $0
Q3 2018

Oct 18, 2018

BUY
$38.6 - $46.12 $38 - $46
1 New
1 $0
Q4 2017

Feb 02, 2018

SELL
$47.69 - $55.39 $5,150 - $5,982
-108 Closed
0 $0
Q3 2017

Oct 24, 2017

BUY
$49.16 - $54.45 $5,309 - $5,880
108
108 $5,000

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.55B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Huntington National Bank Portfolio

Follow Huntington National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Huntington National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Huntington National Bank with notifications on news.